Edesa Biotech (EDSA) Other Non-Current Assets (2013 - 2026)
Edesa Biotech (EDSA) posted Other Non-Current Assets of $40572.0 for Q4 2025, up 1.52% sequentially from $39966.0 in Q3 2025, and up 4.84% YoY from $38698.0 in Q4 2024.
Edesa Biotech (EDSA) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Other Non-Current Assets for 11 years, with the latest figure at $40572.0 in Q4 2025.
- Quarterly Other Non-Current Assets rose 4.84% year-over-year to $40572.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $40572.0 (up 4.84% YoY) and the FY2025 annual result came in at $39966.0, down 2.88% from the prior year.
- Other Non-Current Assets advanced to $40572.0 in Q4 2025 per EDSA's latest filing, from $39966.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $177825.0 in Q2 2023 and troughed at $38698.0 in Q4 2024.
- A 4-year average of $97866.4 and a median of $41109.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets plunged 78.23% in 2024, then climbed 4.84% in 2025.
- Over 4 years, Other Non-Current Assets stood at $173891.0 in 2022, then advanced by 2.21% to $177731.0 in 2023, then slumped by 78.23% to $38698.0 in 2024, then advanced by 4.84% to $40572.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $40572.0, $39966.0, and $40739.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | 39,120.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39,120.00 |
| Dec 31, 2025 | 40,572.00 |
| Sep 30, 2025 | 39,966.00 |
| Jun 30, 2025 | 40,739.00 |
| Mar 31, 2025 | 38,748.00 |
| Dec 31, 2024 | 38,698.00 |
| Sep 30, 2024 | 41,151.00 |
| Jun 30, 2024 | 40,661.00 |
| Mar 31, 2024 | 41,067.00 |
| Dec 31, 2023 | 177,731.00 |
| Sep 30, 2023 | 173,490.00 |
| Jun 30, 2023 | 177,825.00 |
| Mar 31, 2023 | 174,126.00 |
| Dec 31, 2022 | 173,891.00 |
| Sep 30, 2022 | 171,464.00 |
| Jun 30, 2019 | 15,340.00 |
| Mar 31, 2019 | 15,340.00 |
| Sep 30, 2018 | 15,340.00 |
| Jun 30, 2018 | 15,340.00 |
| Mar 31, 2018 | 15,340.00 |